Targeting the circBMPR2/miR-553/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer
Yiran Liang(Qilu Hospital of Shandong University), Qifeng Yang(Qilu Hospital of Shandong University), Peng Su(Qilu Hospital of Shandong University), Renbo Guo(Shandong University), Yuting Sang(Qilu Hospital of Shandong University), Hanwen Zhang(Dongguan People’s Hospital), Ning Zhang(Tianjin Children's Hospital), Ying Liu(Qilu Hospital of Shandong University), Bing Chen(Shanghai Medical College of Fudan University), Xiaoyan Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yaming Li(Qilu Hospital of Shandong University), Xiaojin Song(Qilu Hospital of Shandong University), Wenjing Zhao(Xinjiang Uygur Autonomous Region Product Quality Supervision and Inspection Institute), Lijuan Wang(Pingdingshan University), Tingting Ma(Qilu Hospital of Shandong University), Yi Duan(Beijing Tsinghua Chang Gung Hospital)
Cited by 99
Related Papers
Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets
|Seminars in Cancer Biology|2019|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer
|Molecular Therapy|2019|513
RETRACTED ARTICLE: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis
|Molecular Cancer|2020|396
LncRNA–CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA‐215
|Journal of Cellular Physiology|2018|301